ClinicalTrials.govpublic full text
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
multiple myeloma, relapsed/refractory, mk-3475 & pomalidomide, immunotherapy, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 918426
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.